Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IVX037 + Sintilimab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IVX037 | IVX-037|IVX 037 | IVX037 is an oncolytic RNA virus that selectively infects tumor cells by targeting tumor-specific receptors, potentially leading to induction of cytotoxicity and tumor cell death (NCI Drug Dictionary). | ||
| Sintilimab | IBI308|Tyvyt | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038, PMID: 32656988). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05427487 | Phase I | IVX037 IVX037 + Sintilimab | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |